Zenotech Laboratories Ltd (532039) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532039 | NSE: | Pharmaceuticals & Drugs | Small Cap

Zenotech Laboratorie Share Price

47.38 0.58 1.24%
as on 05-Dec'25 16:59

Zenotech Laboratories Ltd (532039) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532039 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Zenotech Laboratorie

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Zenotech Laboratories stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
92.89
Market Cap:
285.6 Cr.
52-wk low:
46
52-wk high:
77

Is Zenotech Laboratories Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Zenotech Laboratorie: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zenotech Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -65.7%0%-61.9%-6%18.3%0.5%15.3%18.4%12.9%11.5%-
Value Creation
Index
NANA-5.4-1.40.3-1.00.10.3-0.1-0.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2.12.311.1132622.536.642.440.843.140
Sales YoY Gr.-9.2%395.1%17%99.7%-13.7%62.9%16%-3.8%5.4%-
Adj EPS -5.2-5.8-1.9-0.51-0.23.61.91.40.70.5
YoY Gr.-NANANANA-119.2%NA-47.9%-28%-48.5%-
BVPS (₹) -12.7-18.26.96.48.17.911.613.514.815.815.8
Adj Net
Profit
-18.9-21.1-11.8-36.3-1.222.211.68.34.33
Cash Flow from Ops. -4.81.6-16.3-1411.45.717.720.711.89.5-
Debt/CF from Ops. -11.333.20-1.41.63.60.3000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 40.2%10.6%5.6%5.4%
Adj EPS NA-7.6%-42.2%-48.5%
BVPSNA14.1%10.8%6.1%
Share Price 2.9% 10.2% -13.9% -37.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
51.637.799.2-7.514.3-2.537.315.19.64.63.2
Op. Profit
Mgn %
-372.5-460.4-70.5-2634.528.447.848.842.33332.6
Net Profit
Mgn %
-917.4-937.4-106.3-23.324.3-5.460.727.320.49.97.6
Debt to
Equity
-1.2-0.800.50.40.40.10000
Working Cap
Days
8426101482391251117678100120156
Cash Conv.
Cycle
252106-70-42-44-99-6-1017104

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Zenotech Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 0.5 -2.1
TTM Sales (₹ Cr.) 40.2 6.6
BVPS (₹.) 15.8 0
Reserves (₹ Cr.) 35 62
P/BV 2.97 0.00
PE 92.89 0.00
From the Market
52 Week Low / High (₹) 46.00 / 77.00
All Time Low / High (₹) 3.99 / 173.59
Market Cap (₹ Cr.) 286
Equity (₹ Cr.) 61
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Zenotech Laboratorie:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Zenotech Laboratorie - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Zenotech Laboratorie

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales221113262237424143
Operating Expenses 10131917171619222429
Manufacturing Costs25989810111112
Material Costs2211100001
Employee Cost 23556678912
Other Costs 4343222233
Operating Profit -8-10-8-49617211714
Operating Profit Margin (%) -389.0%-461.0%-70.6%-27.0%34.5%28.4%47.8%48.8%42.2%32.9%
Other Income 0025101112
Interest 8820121000
Depreciation 4444567777
Exceptional Items 0200600002
Profit Before Tax -19-20-12-311-110151111
Tax 000000-12335
Profit After Tax -19-20-12-311-1221286
PAT Margin (%) -929.0%-881.0%-106.0%-24.0%41.4%-5.4%60.6%27.3%20.3%13.0%
Adjusted EPS (₹)-5.3-5.5-1.9-0.51.8-0.23.61.91.40.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund -46-664239504871829196
Share Capital 34346161616161616161
Reserves -80-100-19-22-11-1310213035
Minority Interest0000000000
Debt515102019216000
Long Term Debt00000216000
Short Term Debt51510201900000
Trade Payables4554522333
Others Liabilities 4460342113153668
Total Liabilities 5351828586868292100107

Fixed Assets

Gross Block5255565970101105107114116
Accumulated Depreciation481216212734414855
Net Fixed Assets 48474443497471656661
CWIP 002172920524
Investments 0000000000
Inventories2111000010
Trade Receivables0002244337
Cash Equivalents flag 012913122112027
Others Assets 2258534788
Total Assets 5351828586868292100107

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -52-16-141161821129
PBT -19-20-12-311-110151111
Adjustment 12105-0-288764
Changes in Working Capital 212-9-103-110-4-3
Tax Paid 10-0-0-0-0-1-1-1-2
Cash Flow From Investing Activity 5-1-3-16-21-5-2-6-2115
Capex -0-1-4-18-22-5-2-6-4-4
Net Investments 50-11000000
Others 00211000-1719
Cash Flow From Financing Activity -1-14715-30-16-600
Net Proceeds from Shares -001200000000
Net Proceeds from Borrowing -0-0-30-120-15-600
Interest Paid -1-1-19-5-1-2-1-000
Dividend Paid 0000000000
Others 00-51201020000
Net Cash Flow -0028-15-121-09-925

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)N/AN/A0-7.7324.35-2.4837.2615.159.66.01
ROCE (%)N/AN/A-61.88-5.9518.320.4815.2618.3912.8911.46
Asset Turnover Ratio0.040.040.170.160.310.260.440.490.430.42
PAT to CFO Conversion(x)N/AN/AN/AN/A1N/A0.821.751.51.5
Working Capital Days
Receivable Days6228033304639312945
Inventory Days3022032920511080
Payable Days5941,0262,4102,4243,15400001,263

Zenotech Laboratories Ltd Stock News

Zenotech Laboratories Ltd FAQs

The current trading price of Zenotech Laboratorie on 05-Dec-2025 16:59 is ₹47.38.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Zenotech Laboratorie stood at ₹285.6.
The latest P/E ratio of Zenotech Laboratorie as of 04-Dec-2025 is 92.89.
The latest P/B ratio of Zenotech Laboratorie as of 04-Dec-2025 is 2.97.
The 52-week high of Zenotech Laboratorie is ₹77.00 and the 52-week low is ₹46.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zenotech Laboratorie is ₹40.21 ( Cr.) .

About Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.

Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.

Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.

Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.

Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.

Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.

Product range of the company includes:

Generics -- Biological

  • Nugraf
  • Macrogen

        Chemical

  • Gemcitabine for Injection 
  • Paclitaxel for Injection 
  • Docetaxel for Injection 
  • Irinotecan for Injection 
  • Oxaliplatin for Injection 
  • Epirubicin for Injection 
  • Bleomycin for Injection 
  • Cisplatin for Injection 
  • Carboplatin for Injection 
  • Ifosfamide for Injection 
  • Etoposide for Injection

New biologicals Zenotech develops new biological entities in the areas of

  • Cancer
  • Neurology
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×